{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:26:21Z","timestamp":1790281581589,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T00:00:00Z","timestamp":1400198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This analysis from Avastin\u00ae Registries: Investigation of Effectiveness and Safety (ARIES) examined the association between exposure to bevacizumab after disease progression (PD) and postprogression survival (PPS) in bevacizumab\u2010exposed metastatic colorectal cancer (mCRC) through the application of time\u2010dependent and time\u2010fixed analytical methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with mCRC who were treated with first\u2010line bevacizumab and who survived first PD (PD1) were included. A time\u2010dependent Cox regression model was fitted to assess the effect of cumulative bevacizumab exposure on PPS, while controlling for potential confounders. In addition to support findings from previous studies, a modified intent\u2010to\u2010treat (mITT) analysis compared PPS in patients who received bevacizumab beyond disease progression (BBP) with those who did not (No\u2010BBP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1550 patients, 1199 survived PD1 and had a median PPS of 13.4\u2009months. Cumulative bevacizumab exposure was associated with improved PPS (<jats:italic>p<\/jats:italic>\u2009=\u20090.0040). After adjusting for confounders, the hazard ratios (HRs) for PPS decreased, on average, by 1.2% (range, 1.1\u20131.3%) with each additional dose of bevacizumab. In the mITT analysis, the median PPS for BBP (<jats:italic>n<\/jats:italic>\u2009=\u2009438) was 14.4\u2009months vs 10.6\u2009months with for No\u2010BBP (<jats:italic>n<\/jats:italic>\u2009=\u2009667). BBP was found to be independently associated with longer PPS in a multivariable Cox regression analysis (HR, 0.84; 95% confidence interval, 0.73\u20130.97). Protocol\u2010specified adverse events suspected to be associated with bevacizumab occurred in 13.0% of patients with BBP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This analysis supports the observation that bevacizumab exposure after PD1 is associated with longer PPS in mCRC. Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3633","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T08:57:35Z","timestamp":1400230655000},"page":"726-734","source":"Crossref","is-referenced-by-count":46,"title":["Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study"],"prefix":"10.1002","volume":"23","author":[{"given":"Axel","family":"Grothey","sequence":"first","affiliation":[{"name":"Mayo Clinic Medical Oncology  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Dawn","family":"Flick","sequence":"additional","affiliation":[{"name":"Genentech Inc.  South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen L.","family":"Cohn","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Center Medical Oncology  Denver CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios S.","family":"Bekaii\u2010Saab","sequence":"additional","affiliation":[{"name":"The Ohio State University Medical Center Internal Medicine  Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C.","family":"Bendell","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute GI Cancer Research  Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kozloff","sequence":"additional","affiliation":[{"name":"Ingalls Hospital and University of Chicago Hematology and Oncology  Harvey IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Roach","sequence":"additional","affiliation":[{"name":"Fight Colorectal Cancer Patient Advocacy  Alexandria VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mun","sequence":"additional","affiliation":[{"name":"Genentech Inc.  South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fish","sequence":"additional","affiliation":[{"name":"Genentech Inc.  South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert I.","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Division of Hematology and Oncology  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.232"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6305"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.066"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.112"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(12)70477\u20131"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Investigators of the BRiTE study (2009) Clinical outcomes associated with bevacizumab\u2010containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff M","journal-title":"Oncologist"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3212"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.1877"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm324"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181b7fbbb"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072\u20101439.2010.12.07"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2206"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3324"},{"key":"e_1_2_8_16_1","unstructured":"Genentech Inc.Avastin prescribing information.2013."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2011.05.002"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3633","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:17:50Z","timestamp":1696339070000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,16]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1002\/pds.3633"],"URL":"https:\/\/doi.org\/10.1002\/pds.3633","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,16]]}}}